98%
921
2 minutes
20
Background: This study evaluates how AI enhances EHR efficiency by comparing a lung cancer-specific LLM with general-purpose models (DeepSeek, GPT-3.5) and clinicians across expertise levels, assessing accuracy and completeness in complex lung cancer pathology documentation and task load changes pre-/post-AI implementation.
Methods: This study analyzed 300 lung cancer cases (Shanghai Chest Hospital) and 60 TCGA cases, split into training/validation/test sets. Ten clinicians (varying expertise) and three AI models (GPT-3.5, DeepSeek, lung cancer-specific LLM) generated pathology reports. Accuracy/completeness were evaluated against LeapFrog/Joint Commission/ACS standards (non-parametric tests); task load changes pre/post-AI implementation were assessed via NASA-TLX (paired -tests, < 0.05).
Results: This study analyzed 1,390 structured pathology databases: 1,300 from 100 Chinese cases (generated by 10 clinicians and three LLMs) and 90 from 30 TCGA English reports. The lung cancer-specific LLM outperformed nurses, residents, interns, and general AI models (DeepSeek, GPT-3.5) in lesion/lymph node analysis and pathology extraction for Chinese records ( < 0.05), with total scores slightly below chief physicians. In English reports, it matched mainstream AI in lesion analysis ( > 0.05) but excelled in lymph node/pathology metrics ( < 0.05). Task load scores decreased by 38.3% post-implementation (413.90 ± 78.09 vs. 255.30 ± 65.50, = 26.481, < 0.001).
Conclusion: The fine-tuned lung cancer LLM outperformed non-chief physicians and general LLMs in accuracy/completeness, significantly reduced medical staff workload ( < 0.001), with future optimization potential despite current limitations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411430 | PMC |
http://dx.doi.org/10.3389/fmed.2025.1618858 | DOI Listing |
JCO Precis Oncol
September 2025
Shu-Ning Li, MS, Jun-Nv Xu, MD, PhD,and Nan-Nan Ji, MD, PhD, Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, China, Ming Xue, MS, Department of Outpatient, The Second Affiliated Hospital of Hainan Medical University, Hai
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFJCO Precis Oncol
September 2025
Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart
J Bras Pneumol
September 2025
. Rede D'Or, São Paulo (SP), Brasil.
J Bras Pneumol
September 2025
. Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal.
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).
View Article and Find Full Text PDF